It’s time to get MAD

The work you do is important. The last thing you should have to worry about is choosing the right CRISPR nuclease. You deserve licensing access to any application you’re working on.

Providing additional options for CRISPR-based research

The last thing you should have to worry about in product development is choosing the right CRISPR nuclease. You need licensing access to any field or application you wish to work on.

Inscripta developed and released the MAD7 nuclease to the global research community in 2017 under a broad technology access program to democratize access to CRISPR and promote its widespread adoption in both academic and commercial settings.

Inscripta now offers a portfolio of MADzymeTM nucleases under an expanded, non-exclusive licensing program including several MAD variants with improved properties
such as expanded PAM sites, altered activity profiles and higher fidelity. Please contact us below to learn more.

Wild type MAD7 protein is now available as an off-the-shelf product from our trusted partners at Aldevron. See the press release.

Licensing Inquiries
MAD7 nuclease structural model

The MAD7 nuclease in mammalian cells

In addition to robust performance in prokaryotic and eukaryotic microbial systems, the MAD7 nuclease has demonstrated editing activity in mammalian cells.
For example, initial experiments in HEK293T cells show that the MAD7 nuclease can be expressed as an active protein in mammalian cells, and when combined with synthetic guide RNAs, can edit different genes at multiple loci.

How well does it work?

If you are wondering ​“how well does the MAD7 nuclease work?”, we have performed extensive characterization and testing of the MAD7 nuclease in both microbial and mammalian systems. Here you can find the technical data on the editing efficiency and performance in yeast and E. coli, the structure of the MAD7 nuclease and preferred PAM sites, expression recommendations, and how to get started using the MAD7 nuclease in your lab.

View Documents

The MAD7 nuclease in the news

A key part of Inscripta’s mission is making genome engineering more accessible. Read about the recent publications, novel applications, and other MAD7 nuclease news.

See the latest